Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial

Published:2022-10-06 Issue:12 Volume:40 Page:1207-1220
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Keeney Edna^ORCID,Sanghera Sabina,Martin Richard M.,Gulati Roman,Wiklund Fredrik,Walsh Eleanor I.,Donovan Jenny L.,Hamdy Freddie,Neal David E.,Lane J. Athene,Turner Emma L.,Thom Howard,Clements Mark S.

Funder

Cancer Research UK

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-022-01191-1.pdf

Reference57 articles.

1. Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl_5):v69-77.

2. Nam RK, Oliver TK, Vickers AJ, et al. Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion. J Oncol Pract. 2012;8(5):315.

3. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317(19):1949–50.

4. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100–21.

5. Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162(10):718–25.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality;JAMA;2024-05-07

2. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe;European Urology;2024-05

3. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score;BMC Cancer;2024-01-13

4. Point-of-Care Prostate Specific Antigen Testing: Examining Translational Progress toward Clinical Implementation;ACS Sensors;2023-10-13

5. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP);BMC Health Services Research;2023-06-09